Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos, Joannes F. M. Jacobs, Stef J. Koppelman
{"title":"在输血产品中可检测到花生过敏原Ara h6","authors":"Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos, Joannes F. M. Jacobs, Stef J. Koppelman","doi":"10.1002/clt2.12307","DOIUrl":null,"url":null,"abstract":"<p>Peanut allergen Ara h 6 is known to maintain IgE-binding capacity upon exposure to digestive enzymes<span><sup>1</sup></span> and its presence in circulation after consumption of peanut has been demonstrated.<span><sup>2, 3</sup></span> Therefore, it has been speculated that food-derived allergens could be transferred via blood transfusion products, causing an allergic reaction in food-allergic recipients.<span><sup>4, 5</sup></span> However, in published case reports, presence of food allergen in donated material could not be confirmed due to lack of remaining transfusion material and/or lack of sensitive analytical methods. Using a newly developed sensitive immune-assay for detecting Ara h 6 in human serum, we now report to what extent consumed peanut allergens can be present in blood transfusion materials and estimate the associated risk for peanut-allergic recipients.</p><p>When five donors consumed peanut prior to blood donation (all donors gave informed consent to use their blood samples for clinical research, intervals ranging from 4 to 16 h; see methods in Supplementary Information), serum Ara h 6 levels were elevated up to 14 h after consumption (Figure 1). The highest serum Ara h 6 level was 4.20 ng/mL (±1.43 SEM), measured in serum collected 5 h after consumption.</p><p>We use an immunoassay (sandwich ELISA) to detect Ara h 6, and while this demonstrates that Ara h 6 in circulation possesses IgG epitopes, this does not necessarily mean that Ara h 6 in circulation still has allergenic activity. Such can be shown by basophil activation tests, however, within the current setting at our laboratories there was no access to those tests. Others have shown that levels of Ara h 6 detected in circulation after peanut consumption correlate with basophil activation potency<span><sup>3</sup></span> showing that Ara h 6 in circulation is still allergenic, but for our current study we do not have this proof, which is a limitation of our study.</p><p>Adhering to clinical guidelines for routine blood donation, 320 mL units of plasma were also obtained from these donors, at the same intervals after peanut consumption, and a similar pattern of Ara h 6 appearance was observed (Supporting Figures S1 and S2).</p><p>These data were obtained from donors that consumed at one eating occasion a relatively large amount of peanut. To get more insight into the clinical relevance of this observation, plasma samples from 20 adult subjects and a plasma omni pool product obtained from 600 donors (which is a routine transfusion product for clinical use) were analyzed for Ara h 6 content. As per blood donation guidelines, donors had no dietary restrictions and did not receive instruction to consume or avoid peanut. In 17 of the 20 individual plasma samples, Ara h 6 was detected (Figure 2). In eight of these samples, values above LLOQ were measured and two of these samples showed fairly high Ara h 6 levels: 1.09 ng/mL (±0.043 SEM) and 0.66 ng/mL (±0.066 SEM). Differences in Ara h 6 levels across these donors can be due to amount of peanut ingested or due the time between peanut ingestion and blood donation (or a combination of both factors).</p><p>In the plasma omni pool product, 0.56 ng/mL (±0.15 SEM) of Ara h 6 was found.</p><p>It is not known which concentration of peanut allergen in circulation is needed to trigger a systemic reaction in vivo, and if such levels can be reached by blood transfusion, but an estimation can be made using thresholds for basophil activation reported in literature. For example, the in vitro study of Hemmings et al.<span><sup>6</sup></span> showed that 0.1–0.18 ng/mL Ara h 6 triggered basophil degranulation and an ex vivo study of Mose et al.<span><sup>3</sup></span> showed that human serum samples obtained after consumption of peanut, containing 0.025–0.05 ng/mL Ara h 6, can degranulate passively sensitized basophils. However, reported threshold values differ, probably due to differences in methodology, but also due to inter-patient variability of the sensitivity of mast cells and basophils to Ara h 6. The plasma omni pool product investigated in this study would be used in clinical practice at 12–15 mL per kg bodyweight (according to its product data sheet), resulting in a dilution of approximately 3.5–4.5-fold in a recipient. This would result in a modeled Ara h 6 concentration of 0.12–0.16 ng/mL in the recipient's circulation.</p><p>These modeled concentrations of Ara h 6 are in the same order of magnitude as, or somewhat above, the threshold for basophil activation, suggesting that transfusion using a pooled plasma product can trigger an allergic reaction in peanut-allergic recipients. At this stage, no clinical data are available to demonstrate reactivity of Ara h 6 in transfusion products. For example, the role of donor and recipient IgG, which may prevent Ara h 6 to bind to effector cells, needs further exploration. Follow-up studies could include basophil activation assays with (Ara h 6-positive) transfusion material, or similar in vivo experiments with peanut-sensitized animals.</p><p>The importance of other digestion-resistant peanut allergens, like Ara h 2, should be explored as well, as these allergens can further potentiate the allergenic load of transfusion products. For now, only Ara h 6 was considered because no methods are available to detect and quantify other peanut allergens in blood samples.</p><p><b>Fleur A. C. Jansen</b>: Data curation (lead); investigation (lead); validation (equal); visualization (equal); writing—original draft (equal). <b>Klaske van Norren</b>: Methodology (equal); supervision (equal); writing—review and editing (equal). <b>Joseph L. Baumert</b>: Conceptualization (equal); writing—review and editing (equal). <b>Annegeet van den Bos</b>: Resources (equal); writing—review and editing (equal). <b>Joannes F. M. Jacobs</b>: Resources (equal); writing—review and editing (equal). <b>Stef J. Koppelman</b>: Conceptualization (equal); methodology (equal); supervision (equal); validation (equal); writing—original draft (lead).</p><p>Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos and Joannes F. M. Jacobs report no conflict of interest. Stef J. Koppelman is consultant to DBV Technologies, outside the scope of the current paper.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"13 11","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12307","citationCount":"0","resultStr":"{\"title\":\"Peanut allergen Ara h 6 is detectable in blood transfusion products\",\"authors\":\"Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos, Joannes F. M. Jacobs, Stef J. Koppelman\",\"doi\":\"10.1002/clt2.12307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Peanut allergen Ara h 6 is known to maintain IgE-binding capacity upon exposure to digestive enzymes<span><sup>1</sup></span> and its presence in circulation after consumption of peanut has been demonstrated.<span><sup>2, 3</sup></span> Therefore, it has been speculated that food-derived allergens could be transferred via blood transfusion products, causing an allergic reaction in food-allergic recipients.<span><sup>4, 5</sup></span> However, in published case reports, presence of food allergen in donated material could not be confirmed due to lack of remaining transfusion material and/or lack of sensitive analytical methods. Using a newly developed sensitive immune-assay for detecting Ara h 6 in human serum, we now report to what extent consumed peanut allergens can be present in blood transfusion materials and estimate the associated risk for peanut-allergic recipients.</p><p>When five donors consumed peanut prior to blood donation (all donors gave informed consent to use their blood samples for clinical research, intervals ranging from 4 to 16 h; see methods in Supplementary Information), serum Ara h 6 levels were elevated up to 14 h after consumption (Figure 1). The highest serum Ara h 6 level was 4.20 ng/mL (±1.43 SEM), measured in serum collected 5 h after consumption.</p><p>We use an immunoassay (sandwich ELISA) to detect Ara h 6, and while this demonstrates that Ara h 6 in circulation possesses IgG epitopes, this does not necessarily mean that Ara h 6 in circulation still has allergenic activity. Such can be shown by basophil activation tests, however, within the current setting at our laboratories there was no access to those tests. Others have shown that levels of Ara h 6 detected in circulation after peanut consumption correlate with basophil activation potency<span><sup>3</sup></span> showing that Ara h 6 in circulation is still allergenic, but for our current study we do not have this proof, which is a limitation of our study.</p><p>Adhering to clinical guidelines for routine blood donation, 320 mL units of plasma were also obtained from these donors, at the same intervals after peanut consumption, and a similar pattern of Ara h 6 appearance was observed (Supporting Figures S1 and S2).</p><p>These data were obtained from donors that consumed at one eating occasion a relatively large amount of peanut. To get more insight into the clinical relevance of this observation, plasma samples from 20 adult subjects and a plasma omni pool product obtained from 600 donors (which is a routine transfusion product for clinical use) were analyzed for Ara h 6 content. As per blood donation guidelines, donors had no dietary restrictions and did not receive instruction to consume or avoid peanut. In 17 of the 20 individual plasma samples, Ara h 6 was detected (Figure 2). In eight of these samples, values above LLOQ were measured and two of these samples showed fairly high Ara h 6 levels: 1.09 ng/mL (±0.043 SEM) and 0.66 ng/mL (±0.066 SEM). Differences in Ara h 6 levels across these donors can be due to amount of peanut ingested or due the time between peanut ingestion and blood donation (or a combination of both factors).</p><p>In the plasma omni pool product, 0.56 ng/mL (±0.15 SEM) of Ara h 6 was found.</p><p>It is not known which concentration of peanut allergen in circulation is needed to trigger a systemic reaction in vivo, and if such levels can be reached by blood transfusion, but an estimation can be made using thresholds for basophil activation reported in literature. For example, the in vitro study of Hemmings et al.<span><sup>6</sup></span> showed that 0.1–0.18 ng/mL Ara h 6 triggered basophil degranulation and an ex vivo study of Mose et al.<span><sup>3</sup></span> showed that human serum samples obtained after consumption of peanut, containing 0.025–0.05 ng/mL Ara h 6, can degranulate passively sensitized basophils. However, reported threshold values differ, probably due to differences in methodology, but also due to inter-patient variability of the sensitivity of mast cells and basophils to Ara h 6. The plasma omni pool product investigated in this study would be used in clinical practice at 12–15 mL per kg bodyweight (according to its product data sheet), resulting in a dilution of approximately 3.5–4.5-fold in a recipient. This would result in a modeled Ara h 6 concentration of 0.12–0.16 ng/mL in the recipient's circulation.</p><p>These modeled concentrations of Ara h 6 are in the same order of magnitude as, or somewhat above, the threshold for basophil activation, suggesting that transfusion using a pooled plasma product can trigger an allergic reaction in peanut-allergic recipients. At this stage, no clinical data are available to demonstrate reactivity of Ara h 6 in transfusion products. For example, the role of donor and recipient IgG, which may prevent Ara h 6 to bind to effector cells, needs further exploration. Follow-up studies could include basophil activation assays with (Ara h 6-positive) transfusion material, or similar in vivo experiments with peanut-sensitized animals.</p><p>The importance of other digestion-resistant peanut allergens, like Ara h 2, should be explored as well, as these allergens can further potentiate the allergenic load of transfusion products. For now, only Ara h 6 was considered because no methods are available to detect and quantify other peanut allergens in blood samples.</p><p><b>Fleur A. C. Jansen</b>: Data curation (lead); investigation (lead); validation (equal); visualization (equal); writing—original draft (equal). <b>Klaske van Norren</b>: Methodology (equal); supervision (equal); writing—review and editing (equal). <b>Joseph L. Baumert</b>: Conceptualization (equal); writing—review and editing (equal). <b>Annegeet van den Bos</b>: Resources (equal); writing—review and editing (equal). <b>Joannes F. M. Jacobs</b>: Resources (equal); writing—review and editing (equal). <b>Stef J. Koppelman</b>: Conceptualization (equal); methodology (equal); supervision (equal); validation (equal); writing—original draft (lead).</p><p>Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos and Joannes F. M. Jacobs report no conflict of interest. Stef J. Koppelman is consultant to DBV Technologies, outside the scope of the current paper.</p>\",\"PeriodicalId\":10334,\"journal\":{\"name\":\"Clinical and Translational Allergy\",\"volume\":\"13 11\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12307\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12307\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12307","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
已知花生过敏原Ara h6在暴露于消化酶后仍能维持ige结合能力,并且在食用花生后其存在于循环中已得到证实。2,3因此,有人推测食物来源的过敏原可以通过输血制品转移,引起食物过敏接受者的过敏反应。然而,在已发表的病例报告中,由于缺乏剩余的输血材料和/或缺乏敏感的分析方法,无法确认捐赠材料中存在食物过敏原。使用新开发的灵敏免疫测定法检测人血清中的Ara h6,我们现在报告食用花生过敏原可以存在于输血材料中的程度,并估计花生过敏接受者的相关风险。当5名献血者在献血前食用花生(所有献血者知情同意将其血液样本用于临床研究,时间间隔为4至16小时;(见补充信息中的方法),食用后14小时血清Ara h 6水平升高(图1)。食用后5小时采集的血清中Ara h 6水平最高为4.20 ng/mL(±1.43 SEM)。我们使用免疫测定法(夹心ELISA)检测Ara h6,虽然这表明循环中的Ara h6具有IgG表位,但这并不一定意味着循环中的Ara h6仍然具有致敏活性。这可以通过嗜碱性粒细胞激活试验来证明,然而,在我们实验室目前的环境下,没有机会进行这些试验。其他研究表明,食用花生后循环中检测到的Ara h6水平与嗜碱性粒细胞激活能力相关,表明循环中的Ara h6仍然具有致敏性,但就我们目前的研究而言,我们没有这一证据,这是我们研究的局限性。根据临床常规献血指南,在食用花生后,以相同的时间间隔从这些献血者处获得320毫升血浆,观察到类似的Ara h 6外观模式(支持图S1和S2)。这些数据是从一次食用相对大量花生的供体中获得的。为了更深入地了解这一观察结果的临床相关性,对来自20名成人受试者的血浆样本和来自600名献血者的血浆全池产品(这是临床使用的常规输血产品)进行了Ara h 6含量分析。根据献血指南,献血者没有饮食限制,也没有收到食用或避免花生的指示。在20个个体血浆样本中,有17个检测到Ara h 6(图2)。在其中8个样本中,测量到高于LLOQ的值,其中两个样本显示相当高的Ara h 6水平:1.09 ng/mL(±0.043 SEM)和0.66 ng/mL(±0.066 SEM)。这些献血者Ara h 6水平的差异可能是由于摄入花生的量或摄入花生与献血之间的时间(或两种因素的结合)。血浆全能池产品中Ara h6含量为0.56 ng/mL(±0.15 SEM)。目前尚不清楚花生过敏原在血液循环中的浓度是多少才能引发体内的全身反应,也不知道输血是否能达到这样的水平,但可以根据文献中报道的嗜碱性粒细胞激活阈值进行估计。例如,Hemmings等人的体外研究6表明,0.1-0.18 ng/mL Ara h 6可触发嗜碱性粒细胞脱粒;Mose等人的体外研究3表明,食用花生后获得的人血清样品中含有0.025-0.05 ng/mL Ara h 6,可使被动致敏的嗜碱性粒细胞脱粒。然而,报告的阈值不同,可能是由于方法的差异,也可能是由于肥大细胞和嗜碱性粒细胞对Ara h 6的敏感性在患者之间的差异。本研究中研究的血浆全能池产品将在临床实践中以每公斤体重12-15毫升的剂量使用(根据其产品数据表),导致受体稀释约3.5 - 4.5倍。这将导致受体循环中的Ara h 6浓度为0.12-0.16 ng/mL。这些模拟的Ara h6浓度与嗜碱性粒细胞激活的阈值相同,或略高于阈值,这表明使用混合血浆产品输血可以引发花生过敏受体的过敏反应。在这个阶段,没有临床数据证明Ara h6在输血产品中的反应性。例如,供体和受体IgG的作用可能会阻止Ara h6与效应细胞结合,这需要进一步探索。后续研究可能包括(Ara h 6阳性)输血材料的嗜碱性粒细胞激活试验,或类似的花生致敏动物体内实验。 其他抗消化花生过敏原(如Ara h2)的重要性也应加以探讨,因为这些过敏原可以进一步增强输血产品的致敏负荷。目前,只有Ara h6被考虑,因为没有方法可以检测和量化血液样本中的其他花生过敏原。Fleur a.c. Jansen:数据管理(主管);调查(领导);验证(平等);可视化(平等);写作-原稿(同等)。Klaske van Norren:方法论(平等);监督(平等);写作—评审与编辑(同等)。约瑟夫·l·鲍默特:概念化(平等);写作—评审与编辑(同等)。安妮吉特·范登·博斯:资源(相等);写作—评审与编辑(同等)。乔安娜·f·m·雅各布斯:资源(平等);写作—评审与编辑(同等)。Stef J. Koppelman:概念化(平等);方法(平等);监督(平等);验证(平等);写作——原稿(引子)。Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos和Joannes F. M. Jacobs报告没有利益冲突。Stef J. Koppelman是DBV Technologies的顾问,超出了本文的范围。
Peanut allergen Ara h 6 is detectable in blood transfusion products
Peanut allergen Ara h 6 is known to maintain IgE-binding capacity upon exposure to digestive enzymes1 and its presence in circulation after consumption of peanut has been demonstrated.2, 3 Therefore, it has been speculated that food-derived allergens could be transferred via blood transfusion products, causing an allergic reaction in food-allergic recipients.4, 5 However, in published case reports, presence of food allergen in donated material could not be confirmed due to lack of remaining transfusion material and/or lack of sensitive analytical methods. Using a newly developed sensitive immune-assay for detecting Ara h 6 in human serum, we now report to what extent consumed peanut allergens can be present in blood transfusion materials and estimate the associated risk for peanut-allergic recipients.
When five donors consumed peanut prior to blood donation (all donors gave informed consent to use their blood samples for clinical research, intervals ranging from 4 to 16 h; see methods in Supplementary Information), serum Ara h 6 levels were elevated up to 14 h after consumption (Figure 1). The highest serum Ara h 6 level was 4.20 ng/mL (±1.43 SEM), measured in serum collected 5 h after consumption.
We use an immunoassay (sandwich ELISA) to detect Ara h 6, and while this demonstrates that Ara h 6 in circulation possesses IgG epitopes, this does not necessarily mean that Ara h 6 in circulation still has allergenic activity. Such can be shown by basophil activation tests, however, within the current setting at our laboratories there was no access to those tests. Others have shown that levels of Ara h 6 detected in circulation after peanut consumption correlate with basophil activation potency3 showing that Ara h 6 in circulation is still allergenic, but for our current study we do not have this proof, which is a limitation of our study.
Adhering to clinical guidelines for routine blood donation, 320 mL units of plasma were also obtained from these donors, at the same intervals after peanut consumption, and a similar pattern of Ara h 6 appearance was observed (Supporting Figures S1 and S2).
These data were obtained from donors that consumed at one eating occasion a relatively large amount of peanut. To get more insight into the clinical relevance of this observation, plasma samples from 20 adult subjects and a plasma omni pool product obtained from 600 donors (which is a routine transfusion product for clinical use) were analyzed for Ara h 6 content. As per blood donation guidelines, donors had no dietary restrictions and did not receive instruction to consume or avoid peanut. In 17 of the 20 individual plasma samples, Ara h 6 was detected (Figure 2). In eight of these samples, values above LLOQ were measured and two of these samples showed fairly high Ara h 6 levels: 1.09 ng/mL (±0.043 SEM) and 0.66 ng/mL (±0.066 SEM). Differences in Ara h 6 levels across these donors can be due to amount of peanut ingested or due the time between peanut ingestion and blood donation (or a combination of both factors).
In the plasma omni pool product, 0.56 ng/mL (±0.15 SEM) of Ara h 6 was found.
It is not known which concentration of peanut allergen in circulation is needed to trigger a systemic reaction in vivo, and if such levels can be reached by blood transfusion, but an estimation can be made using thresholds for basophil activation reported in literature. For example, the in vitro study of Hemmings et al.6 showed that 0.1–0.18 ng/mL Ara h 6 triggered basophil degranulation and an ex vivo study of Mose et al.3 showed that human serum samples obtained after consumption of peanut, containing 0.025–0.05 ng/mL Ara h 6, can degranulate passively sensitized basophils. However, reported threshold values differ, probably due to differences in methodology, but also due to inter-patient variability of the sensitivity of mast cells and basophils to Ara h 6. The plasma omni pool product investigated in this study would be used in clinical practice at 12–15 mL per kg bodyweight (according to its product data sheet), resulting in a dilution of approximately 3.5–4.5-fold in a recipient. This would result in a modeled Ara h 6 concentration of 0.12–0.16 ng/mL in the recipient's circulation.
These modeled concentrations of Ara h 6 are in the same order of magnitude as, or somewhat above, the threshold for basophil activation, suggesting that transfusion using a pooled plasma product can trigger an allergic reaction in peanut-allergic recipients. At this stage, no clinical data are available to demonstrate reactivity of Ara h 6 in transfusion products. For example, the role of donor and recipient IgG, which may prevent Ara h 6 to bind to effector cells, needs further exploration. Follow-up studies could include basophil activation assays with (Ara h 6-positive) transfusion material, or similar in vivo experiments with peanut-sensitized animals.
The importance of other digestion-resistant peanut allergens, like Ara h 2, should be explored as well, as these allergens can further potentiate the allergenic load of transfusion products. For now, only Ara h 6 was considered because no methods are available to detect and quantify other peanut allergens in blood samples.
Fleur A. C. Jansen: Data curation (lead); investigation (lead); validation (equal); visualization (equal); writing—original draft (equal). Klaske van Norren: Methodology (equal); supervision (equal); writing—review and editing (equal). Joseph L. Baumert: Conceptualization (equal); writing—review and editing (equal). Annegeet van den Bos: Resources (equal); writing—review and editing (equal). Joannes F. M. Jacobs: Resources (equal); writing—review and editing (equal). Stef J. Koppelman: Conceptualization (equal); methodology (equal); supervision (equal); validation (equal); writing—original draft (lead).
Fleur A. C. Jansen, Klaske van Norren, Joseph L. Baumert, Annegeet van den Bos and Joannes F. M. Jacobs report no conflict of interest. Stef J. Koppelman is consultant to DBV Technologies, outside the scope of the current paper.
期刊介绍:
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience.
Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.